Ocugen, Inc. Files 8-K Report

Ticker: OCGN · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1372299

Ocugen, INC. 8-K Filing Summary
FieldDetail
CompanyOcugen, INC. (OCGN)
Form Type8-K
Filed DateJun 17, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, corporate-update

TL;DR

Ocugen filed an 8-K on 6/16/25. Standard update.

AI Summary

On June 16, 2025, Ocugen, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delaware, is involved in biological products, specifically excluding diagnostic substances, and is headquartered at 11 Great Valley Parkway, Malvern, PA.

Why It Matters

This filing provides an update on Ocugen's corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not contain significant new information that would inherently increase risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of June 16, 2025.

What is Ocugen, Inc.'s state of incorporation?

Ocugen, Inc. is incorporated in Delaware.

What is the business address and phone number for Ocugen, Inc.?

The business address is 11 Great Valley Parkway, Malvern, Pennsylvania 19355, and the phone number is (484) 328-4701.

What is the SIC code for Ocugen, Inc.?

The Standard Industrial Classification (SIC) code is 2836, which pertains to Biological Products (No Diagnostic Substances).

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on June 16, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding Ocugen, Inc. (OCGN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing